All

Another milestone for Reboat, a French pioneer in sailboat refurbishment: Seventure Partners takes a stake in the company to accelerate its growth
23 July 2026

Another milestone for Reboat, a French pioneer in sailboat refurbishment: Seventure Partners takes a stake in the company to accelerate its growth

Reboat announces the closing of a funding round led by Seventure Partners, alongside existing investors and business angels, including Charlotte Souleau, Managing Director for...

Read the press release
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21 July 2026

Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced new positive interim data...

Read more
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28 May 2026

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced that the U.S. Food and...

Read more
vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty
27 May 2026

vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty

VorteX -io Raises €8.5 Million from Seventure Partners, Banque des Territoires, and Daphni to Turn Hydrological Data into a Lever for National Sovereignty and Address Global...

Read more
Social AdTech firm Mediads raises €3 million to accelerate its expansion into the US
19 May 2026

Social AdTech firm Mediads raises €3 million to accelerate its expansion into the US

Mediads, a pioneering social adtech company since 2022 specialising in social publishing, which
offers a platform designed to boost the performance of

Read more
Microbiotica reports positive results for MB097 in advanced melanoma
18 May 2026

Microbiotica reports positive results for MB097 in advanced melanoma

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment.

Microbiotica has announced positive findings from its phase 1b MELODY‑1...

Read more
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12 May 2026

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-target in vivo immune therapies shown to induce a rapid, long-lasting and...

Read more
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
15 April 2026

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013

Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting...

Read more
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
2 April 2026

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the...

Read more
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31 March 2026

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-
generation proteins, has announced a $34.2 million (€30 million) Series...

Read the press release